Previous close | 0.3000 |
Open | 0.1600 |
Bid | 0.0200 |
Ask | 0.4300 |
Strike | 45.00 |
Expiry date | 2023-01-20 |
Day's range | 0.1600 - 0.2300 |
Contract range | N/A |
Volume | |
Open interest | 1.47k |
One great way to make passive income is to invest in dividend stocks. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings.
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
AbbVie today shared findings from the newly launched Emotional Impact Report, a survey of more than 300 chronic lymphocytic leukemia (CLL) patients, caregivers and healthcare providers (HCPs), which uncovered insights about the emotional journey associated with a CLL diagnosis.